CO2019007188A2 - Secuelas de lesión pulmonar inducida por baipás cardiopulmonar - Google Patents

Secuelas de lesión pulmonar inducida por baipás cardiopulmonar

Info

Publication number
CO2019007188A2
CO2019007188A2 CONC2019/0007188A CO2019007188A CO2019007188A2 CO 2019007188 A2 CO2019007188 A2 CO 2019007188A2 CO 2019007188 A CO2019007188 A CO 2019007188A CO 2019007188 A2 CO2019007188 A2 CO 2019007188A2
Authority
CO
Colombia
Prior art keywords
cardiopulmonary
sequelae
injury induced
pulmonary injury
pulmonary
Prior art date
Application number
CONC2019/0007188A
Other languages
English (en)
Inventor
Marshall Summar
Frederick Barr
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of CO2019007188A2 publication Critical patent/CO2019007188A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Amplifiers (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método para administrar citrulina a un paciente durante la cirugía sin filtración de la hemólisis para reducir el desacoplamiento del dímero de la enzima eNOS que conduce a lesión pulmonar inducida por baipás cardiopulmonar.
CONC2019/0007188A 2016-12-28 2019-07-03 Secuelas de lesión pulmonar inducida por baipás cardiopulmonar CO2019007188A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662439772P 2016-12-28 2016-12-28
PCT/US2017/068698 WO2018125999A1 (en) 2016-12-28 2017-12-28 Sequelae of cardiopulmonary bypass-induced pulmonary injury

Publications (1)

Publication Number Publication Date
CO2019007188A2 true CO2019007188A2 (es) 2019-07-31

Family

ID=62710740

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0007188A CO2019007188A2 (es) 2016-12-28 2019-07-03 Secuelas de lesión pulmonar inducida por baipás cardiopulmonar

Country Status (14)

Country Link
US (1) US10265286B2 (es)
EP (1) EP3506892B1 (es)
JP (1) JP7236384B2 (es)
KR (1) KR102327069B1 (es)
CN (1) CN109922799B (es)
AR (1) AR110663A1 (es)
AU (2) AU2017388398A1 (es)
BR (1) BR112019007245A2 (es)
CA (1) CA3048432A1 (es)
CO (1) CO2019007188A2 (es)
IL (2) IL300046A (es)
MX (1) MX2019005670A (es)
RU (1) RU2762593C2 (es)
WO (1) WO2018125999A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230404956A1 (en) * 2022-06-21 2023-12-21 Asklepion Pharmaceuticals Llc Therapeutic window for citrulline therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486429B2 (en) 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6346382B1 (en) 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
CN101083589B (zh) 2007-07-13 2010-08-11 华为技术有限公司 无源光网络中的终端检测认证方法、装置及操作管理系统
KR20100135729A (ko) 2008-01-31 2010-12-27 반더빌트유니버시티 폐의 용태에 따른 치료 방법
WO2017004233A1 (en) 2015-06-29 2017-01-05 Vanderbilt University Intravenous administration of citrulline during surgery

Also Published As

Publication number Publication date
BR112019007245A2 (pt) 2019-07-02
MX2019005670A (es) 2019-08-12
IL300046A (en) 2023-03-01
RU2019123427A (ru) 2021-01-29
CN109922799A (zh) 2019-06-21
CA3048432A1 (en) 2018-07-05
KR20190101363A (ko) 2019-08-30
CN109922799B (zh) 2021-11-16
US20180214403A1 (en) 2018-08-02
RU2019123427A3 (es) 2021-05-20
EP3506892A4 (en) 2020-05-06
EP3506892A1 (en) 2019-07-10
IL267707A (en) 2019-08-29
RU2762593C2 (ru) 2021-12-21
WO2018125999A1 (en) 2018-07-05
KR102327069B1 (ko) 2021-11-16
AR110663A1 (es) 2019-04-17
JP7236384B2 (ja) 2023-03-09
US10265286B2 (en) 2019-04-23
AU2024200984A1 (en) 2024-03-07
AU2017388398A1 (en) 2019-05-23
JP2020503326A (ja) 2020-01-30
EP3506892B1 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
EA201790398A1 (ru) Способы лечения заболевания печени
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201692436A1 (ru) Медицинское применение
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
BR112016018548A2 (pt) composto, ácido, medicamento, e, uso de um composto.
SV2018005682A (es) Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
CY1126036T1 (el) Δοσολογικο σχημα σακουμπιτριλης-βαλσαρτανης για τη θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας
BR112016025470A2 (pt) ?hdl terapêutico?
MX2016010651A (es) Vacunas de virus aviar que son estables en liquido.
CY1124759T1 (el) Μεθοδοι για τη θεραπεια της οξειας νεφρικης βλαβης
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
DOP2017000098A (es) Compuesto heterocíclico
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
CL2016002779A1 (es) Composición para el cuidado de la piel
ECSP16096831A (es) Derivados de naftiridinadiona
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
CO2019007188A2 (es) Secuelas de lesión pulmonar inducida por baipás cardiopulmonar
CY1123243T1 (el) Ενωση προερχομενη απο πυραζολινη και η χρηση τησσε ενα θεραπευτικο σχημα εβδομαδιαιας δοσολογησης εναντια στην φλεγμονη και τον πονο που προερχονται απο την εκφυλιστικη ασθενεια των αρθρωσεων στα θηλαστικα
EA201891008A3 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
EA201692371A1 (ru) 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
EA201691218A1 (ru) Агонисты a1-аденозиновых рецепторов в качестве лекарственного средства для лечения заболеваний почек
CY1124271T1 (el) Παραγοντας αγωγης της δερματομυκωσης που περιλαμβανει κιτρικο τρικαλιο
CY1121388T1 (el) Παραγωγα βενζυλυδροξειδιου, παρασκευη αυτων και θεραπευτικη χρηση αυτων